Most Read Articles
Tristan Manalac, 6 days ago
Incorporating genotyping of human adenovirus (HAdV) infections in clinical practice may inform risk stratification and treatment decisions, according to a new Singapore study.
Tristan Manalac, 25 Oct 2019
Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.
4 days ago
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.
Tristan Manalac, 04 Sep 2019
A booster injection of CYD-TDV (Dengvaxia) can generally restore antidengue antibody titres 5 years after a three-dose schedule, according to a new Singapore study.

Tenofovir better than entecavir for minimizing HCC risk in HBV

23 Jan 2020

Tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) infection suppresses hepatocellular carcinoma (HCC) risk better than entecavir, a new study has found.

Researchers retrospectively assessed 29,350 HBV patients (mean age, 52.9±13.2 years; 63.7 percent male) who had received first-line treatment with either TDF (n=1,309; 4.5 percent) or entecavir (n=28,041; 95.5 percent). Participants were followed for 3.6 years for the determination of the cumulative incidence of HCC.

A total of 1,394 patients developed HCC over the observation period, yielding an incidence rate of 4.7 percent. The 1-, 3-, and 5-year cumulative incidence estimates were 1.2 percent, 4.3 percent and 6.8 percent, respectively. Only eight of the HCC cases occurred in the TDF arm (0.6 percent), while the remaining 1,386 (4.9 percent) had been treated with entecavir.

After propensity score matching, patients who were treated with TDF showed a significantly lower risk of developing HCC than their entecavir counterparts (weighted subdistribution hazard ratio [SHR], 0.39, 95 percent confidence interval [CI], 0.18–0.84; p=0.016). This remained true even when analysis was restricted to noncirrhotic patients (weighted SHR, 0.15, 95 percent CI, 0.03–0.74; p=0.02).

The 1-, 3-, and 5-year cumulative incidence rates of HCC in entecavir- vs TDF-treated patients were 0.4 percent vs 0.1 percent, 1.3 percent vs 0.7 percent, and 2.2 percent vs 1.2 percent, respectively.

The present findings warrant further validation in other populations, said researchers. “Future prospective studies would also be valuable to confirm our observations.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 6 days ago
Incorporating genotyping of human adenovirus (HAdV) infections in clinical practice may inform risk stratification and treatment decisions, according to a new Singapore study.
Tristan Manalac, 25 Oct 2019
Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.
4 days ago
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.
Tristan Manalac, 04 Sep 2019
A booster injection of CYD-TDV (Dengvaxia) can generally restore antidengue antibody titres 5 years after a three-dose schedule, according to a new Singapore study.